Real-world pan-cancer study shows methylation biomarkers predict rwPFS in patients receiving immune checkpoint inhibitors, indicating enhanced treatment selection methods.
A–E, MR outcome prediction is complementary to RECIST in subset of patients with 6-month best RECIST response available (n = 75). Kaplan–Meier plots for rwPFS. A, RECIST association with rwPFS by two groups combining CR/PR/SD vs. PD. B, MR and nMR at any timepoint association with rwPFS in the RECIST subset. C, Waterfall plot of greatest percentage TF change (best MR) within 6 months by RECIST response. D, SD patients stratified by MR and nMR at any timepoint and association with rwPFS (n = 31). E, Forest plot of the CPH model with RECIST included (CR/PR/SD vs. PD) as a covariate.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: